iiinova — where your digital self keeps evolving

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 20/04/2026

So well deserved! truly inspiring work in cancer research. Congrats Eli! #AACR26

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 13/01/2025

I'm running the Chicago Marathon with Crohn’s & Colitis Foundation Team Challenge to support those affected by Crohn's & Colitis. Join me in making a difference—every donation brings us closer to better treatments and a cure! 🏃‍♂️💙 Donate here: teamchallenge.crohnscolitisfoundation.org/index.cfm?fu...

teamchallenge.crohnscolitisfoundation.org

I'm fundraising for IBD cures!

I am participating in the 2025 Bank of America Chicago Marathon and raising funds for the Crohn’s & Colitis Foundation. With every mile, I hope to further their mission of finding cures for Crohn's di...

010

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 29/11/2024

9/10 Clinical implications: Our model provides additional predictive power beyond existing biomarkers like TMB and IFN-γ signatures. It complements clinical features to better stratify patients for personalized immunotherapy

100

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 29/11/2024

8/10 Independent validation: Using paired targeted NGS panels (MSK-IMPACT): - Ploidy estimates were consistent with WES. - TNGS shows promise for broader clinical adoption.

110

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 29/11/2024

7/10 Subtype insights: Non-cutaneous melanoma subtypes (e.g., Acral, Mucosal) showed: ⬆️ Higher heterogeneity ⬆️ WGD incidence Cutaneous melanomas exhibited heterogeneity driven by non-UV mutational processes.

100

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 29/11/2024

6/10 Beyond response prediction: - Timing of whole genome doubling (WGD) affects resistance: Tumors with recent WGD (high proportion of SNV with multiplicity of 2) showed high resistance despite low heterogeneity.

100

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 29/11/2024

5/10 Model performance: Our decision tree model using heterogeneity & ploidy achieved: ✅ High specificity (97%) ✅ Strong PPV (90%) This helps identify patients unlikely to benefit from single-agent aPD-1 ICB, who might need combo therapies.

110

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 29/11/2024

4/10 Why does this matter? integrating TCGA data we show that: - Genomic heterogeneity predicts therapy resistance. - Ploidy offers prognostic value. Together, they provide a precise and independent biomarker system to improve clinical decision-making. 🔬

110

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 29/11/2024

3/10 Main findings: Across different cohorts, low ploidy 📉 and high heterogeneity 📈 robustly identify patients with intrinsic resistance to aPD-1 therapy

100

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 29/11/2024

2/10 What we did: - Harmonized data across independent metastatic melanoma cohorts. - Focused on ICB-naïve patients treated with aPD-1 therapy. - Used whole-exome sequencing (WES), bulkRNAseq and clinical annotations.

110

Giuseppe Tarantino, PhD @giuseppetara.bsky.social · 29/11/2024

1/10🚨 New Findings Alert! 🚨 Discover how genomic heterogeneity and ploidy help predict intrinsic resistance to anti-PD-1 immune checkpoint blockade (ICB) in metastatic melanoma. 🧬https://www.science.org/doi/10.1126/sciadv.adp4670 📝 Key takeaways from our latest study: 🧵👇

131